Marksans Pharma

Marksans Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Marksans Pharma (MARKSANS.NS) as of Oct 25, 2026 is 227.32. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 375.03 — a change of -39.39% (lower).

EV/FCF

227.32

YoY

-39.39%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Marksans Pharma is 2025 227.32 . EV/FCF (Enterprise Value to Free Cash Flow) of Marksans Pharma was 2024 375.03 . It decreases by -39.39% lower compared to the previous year.

The Marksans Pharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
732.90 INR
Jan 1, 2019
573.11 INR
Jan 1, 2020
53.35 INR
Jan 1, 2021
59.80 INR
Jan 1, 2022
147.85 INR
Jan 1, 2023
40.71 INR
Jan 1, 2024
375.03 INR
Jan 1, 2025
227.32 INR
The Marksans Pharma EV/FCF history
YEAREV/FCFYoY
227.32-39.39%
375.03+821.29%
40.71-72.47%
147.85+147.23%
59.80+12.10%
53.35-90.69%
573.11-21.80%
732.90-269.30%
-432.90+436.59%
-80.68-215.99%
69.56-50.21%
139.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Marksans Pharma Stock analysis

What does Marksans Pharma do? Marksans Pharma Ltd. generates revenue through the research, manufacturing, marketing, and sale of pharmaceutical formulations across multiple therapeutic areas including pain management, cough and cold, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic products. The company operates four manufacturing facilities in India, the United Kingdom, and the United States, producing oral solid tablets, soft gelatin capsules, hard capsules, non-sterile liquids, ointments, and powders. Its products are distributed to markets in the United Kingdom, West Africa, and the Middle East, with manufacturing facilities in Goa, the United Kingdom, and the United States catering to these regions. The firm's primary revenue streams come from the sale of pharmaceutical formulations manufactured at its facilities in Goa, the United Kingdom, and the United States. The company's product portfolio spans various therapeutic segments, with manufacturing capabilities for tablets, capsules, liquids, ointments, and powders. Its facilities in Goa and the United Kingdom serve the United Kingdom, West Africa, and the Middle East markets, while the U.S. facility focuses on domestic and international distribution of tablet and capsule products. Marksans Pharma Ltd. sells its pharmaceutical formulations to healthcare providers, pharmacies, and distributors across multiple regions. The company's manufacturing facilities in Goa, the United Kingdom, and the United States support its global distribution network, with specific facilities dedicated to serving the United Kingdom, West Africa, and the Middle East markets through non-sterile liquid, ointment, and powder products. The firm's product range includes pain management, cough and cold, cardiovascular, and anti-diabetic formulations, among others, sold to customers in the specified regions. Marksans Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Marksans Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Marksans Pharma is 227.32 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Marksans Pharma changed from 375.03 to 227.32, representing a -39.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Marksans Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Marksans Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Marksans Pharma

All Key Metrics — Marksans Pharma